Advances in Hormone Receptor Positive Metastatic Breast Cancer

Aditya Bardia, MD, MPH, discusses the current standard of care for HR+ advanced breast cancer and reacts to treatment advances with the availability of CDK4/6 inhibitors.

Options available as first-line therapy for HR+ metastatic breast cancer and variables that impact which CDK4/6 inhibitor and endocrine partner is selected for a patient.

Important takeaways from MONALEESA-2 trial updates on overall survival data corresponding with the use of ribociclib plus letrozole, as presented at ESMO 2021.

Considerations for treating HR+ metastatic breast cancer with ribociclib plus endocrine therapy based on quality-of-life metrics demonstrated by a recent ESMO 2021 presentation.

Clinical implications of a pooled analysis of endocrine therapy-naïve participants in MONARCH 2 investigating the use of abemaciclib plus fulvestrant to treat hormone receptor-positive metastatic breast cancer.

The rationale for conducting a post-hoc analysis of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor-positive metastatic breast cancer as presented at ESMO 2021.

A discussion on the current utilization of molecular testing in patients with HR-positive metastatic breast cancer, and recommendations for conducting liquid and tissue biopsies to help inform treatment decisions.

The relevance of PIK3CA mutations in terms of the pathophysiology of HR-positive metastatic breast cancer, and lessons learned in practice and via clinical studies in terms of sequencing therapy with PI3K inhibitors.

An overview of key presentations from ESMO 2021 that continues studying the potential effect of novel-based treatment options for use in hormone receptor-positive metastatic breast cancer.

Various breast oncologists discuss the potential effect of treatment advances in hormone receptor-positive metastatic breast cancer.